BlackRock
NVLN

BlackRock’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

BlackRock’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,289
Closed -$2K – 5133
2019
Q2 		$2K Sell
3,289
-37,825
-92% -$42.1K ﹤0.01% 4933
2019
Q1 		$51K Sell
41,114
-2,814
-6% -$3.2K ﹤0.01% 4476
2018
Q4 		$37K Sell
43,928
-804
-2% -$908 ﹤0.01% 4515
2018
Q3 		$132K Buy
44,732
+1,809
+4% +$6.4K ﹤0.01% 4405
2018
Q2 		$158K Sell
42,923
-637,682
-94% -$2.56M ﹤0.01% 4370
2018
Q1 		$2.38M Sell
680,605
-10,259
-1% -$43.5K ﹤0.01% 3637
2017
Q4 		$2.15M Buy
690,864
+11,375
+2% +$54.7K ﹤0.01% 3672
2017
Q3 		$4.78M Buy
679,489
+13,028
+2% +$104K ﹤0.01% 3476
2017
Q2 		$6.15M Buy
666,461
+654,842
+5,636% +$6.31M ﹤0.01% 3403
2017
Q1 		$125K Buy
11,619
+6,117
+111% +$62.5K ﹤0.01% 4297
2016
Q4 		$46K Buy
+5,502
New +$48.7K ﹤0.01% 2980

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

BlackRock's NVLN Position: Q3 2019 in Review

BlackRock sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2019, closing a stake of 3,289 shares — an estimated $2K sold.

BlackRock first reported a position in NVLN in Q4 2016 and held it in 11 quarters. The position peaked at $6.15M in Q2 2017. 31 funds tracked by Wall St. Rank hold NVLN as of Q3 2019.

  • BlackRock reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2019 after selling out during the quarter.
  • BlackRock sold 3,289 Novelion Therapeutics Inc. Common Shares shares in Q3 2019, an estimated $2K.
  • BlackRock first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 11 quarters.
  • BlackRock's Novelion Therapeutics Inc. Common Shares position peaked at $6.15M in Q2 2017.
  • 31 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2019.

Based on BlackRock's 13F filing for Q3 2019, filed 8 Nov 2019.